Midwest Financial Partners Investments Inc. Invests $480,000 in Illumina, Inc. $ILMN

Midwest Financial Partners Investments Inc. purchased a new stake in Illumina, Inc. (NASDAQ:ILMN) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 3,662 shares of the life sciences company’s stock, valued at approximately $480,000.

Several other institutional investors have also bought and sold shares of the stock. MassMutual Private Wealth & Trust FSB boosted its stake in Illumina by 7.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,081 shares of the life sciences company’s stock valued at $142,000 after buying an additional 79 shares in the last quarter. HighPoint Advisor Group LLC lifted its holdings in Illumina by 3.7% during the 4th quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock valued at $291,000 after purchasing an additional 80 shares during the last quarter. Assetmark Inc. lifted its holdings in Illumina by 10.2% during the 3rd quarter. Assetmark Inc. now owns 1,039 shares of the life sciences company’s stock valued at $99,000 after purchasing an additional 96 shares during the last quarter. Venturi Wealth Management LLC lifted its holdings in Illumina by 4.2% during the 4th quarter. Venturi Wealth Management LLC now owns 2,465 shares of the life sciences company’s stock valued at $323,000 after purchasing an additional 99 shares during the last quarter. Finally, Banque Cantonale Vaudoise lifted its holdings in Illumina by 1.5% during the 4th quarter. Banque Cantonale Vaudoise now owns 7,071 shares of the life sciences company’s stock valued at $927,000 after purchasing an additional 107 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Insiders Place Their Bets

In related news, Director Keith A. Meister sold 104,393 shares of the company’s stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $145.34, for a total value of $15,172,478.62. Following the completion of the sale, the director owned 3,500,048 shares in the company, valued at $508,696,976.32. This represents a 2.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Christensen Jakob Wedel sold 700 shares of the company’s stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total transaction of $97,328.00. Following the completion of the sale, the senior vice president owned 15,056 shares of the company’s stock, valued at approximately $2,093,386.24. This represents a 4.44% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 330,160 shares of company stock valued at $48,028,308. 2.90% of the stock is owned by corporate insiders.

Illumina Price Performance

Shares of ILMN opened at $144.83 on Friday. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. Illumina, Inc. has a 1 year low of $78.55 and a 1 year high of $155.53. The stock has a market cap of $21.91 billion, a P/E ratio of 26.33, a price-to-earnings-growth ratio of 2.35 and a beta of 1.42. The stock’s 50-day moving average price is $129.99 and its two-hundred day moving average price is $130.81.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The firm had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter last year, the business earned $0.97 earnings per share. The company’s revenue was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, equities analysts predict that Illumina, Inc. will post 5.2 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ILMN has been the topic of a number of research analyst reports. Weiss Ratings lowered Illumina from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, April 29th. Piper Sandler decreased their price target on Illumina from $195.00 to $170.00 and set an “overweight” rating on the stock in a research report on Monday, February 9th. Royal Bank Of Canada started coverage on shares of Illumina in a research report on Thursday, May 14th. They issued an “outperform” rating and a $170.00 price objective for the company. Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price objective for the company in a research report on Thursday, May 14th. Finally, Guggenheim upped their price target on Illumina from $144.00 to $170.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Seven analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Illumina presently has an average rating of “Hold” and a consensus price target of $137.75.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.